Contineum Therapeutics (CTNM) Stock Price, News & Analysis

Company Overview

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological and neuroinflammatory diseases. The company’s research is centered on restoring nervous-system function and addressing conditions in which inflammation or damage to myelin contributes to disease progression.

Contineum’s lead programs include PIPE-307, an oral, selective M1 muscarinic receptor antagonist being studied for its potential to promote remyelination in multiple sclerosis, and PIPE-791, an oral, central nervous system-penetrant LPA1 antagonist being developed for progressive multiple sclerosis and other fibrotic or neuroinflammatory conditions. The programs are intended to address significant areas of unmet medical need where available treatment options may not adequately repair neurological damage or control disease progression.

The company was formerly known as Pipeline Therapeutics and adopted the Contineum Therapeutics name as it advanced its development pipeline. Based in San Diego, California, Contineum serves the global biopharmaceutical market through the research and clinical development of therapies for neurological and inflammatory diseases.

Key Stats

• Today's Range: $8.01 to $8.43
• 50-Day Range: $7.08 to $17.57
• 52-Week Range: $6.72 to $17.78
• Volume: 428,770 shs
• Average Volume: 1.45 million shs
• Market Capitalization: $312.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.33
• Consensus Rating: Hold

Contineum Therapeutics Stock Analysis - MarketRank™

Contineum Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 499th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Contineum Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Contineum Therapeutics has a consensus price target of $22.33, representing about 168.8% upside from its current price of $8.31.

Amount of Analyst Coverage

Contineum Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Contineum Therapeutics are expected to grow in the coming year, from ($1.68) to ($1.64) per share.

Price to Book Value per Share Ratio

Contineum Therapeutics has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.85% of the float of Contineum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Contineum Therapeutics has a short interest ratio ("days to cover") of 3.62, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Contineum Therapeutics has recently increased by 25.53%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Contineum Therapeutics does not currently pay a dividend.

Dividend Growth

Contineum Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Contineum Therapeutics this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for CTNM on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Contineum Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.90% of the stock of Contineum Therapeutics is held by insiders.

Percentage Held by Institutions

Contineum Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/25/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CTNM
• Previous Symbol: NASDAQ:CTNM
• CIK: 1855175
• Web: www.contineum-tx.com
• Phone: (858) 333-5280
• Fax: N/A
• Employees: 51
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Contineum Therapeutics: $22.33
• High Price Target: $30.00
• Low Price Target: $14.00
• Potential Upside/Downside: +168.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -24.73%
• Return on Assets: -23.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 37.17
• Quick Ratio: 37.17

Sales & Book Value

• Annual Sales: $50 million
• Price / Sales: 6.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.99 per share
• Price / Book: 1.19

Miscellaneous

• Outstanding Shares: 37,620,000
• Free Float: 34,649,000
• Market Cap: $312.62 million
• Optionable: Optionable
• Beta: 0.86